How to develop a sustainable portfolio for cell, gene therapy platforms
June 13, 2022 -- Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke to ScienceBoard.net about his company’s transition from a research center to a private, venture-backed startup and a publicly traded company. Read More
Biotech industry execs, not scientists, remain male-dominated
June 13, 2022 -- A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and how it can become more inclusive. ScienceBoard.net spoke with Nasha Fitter, co-founder and CEO of the FOXG1 Research Foundation, who will participate in the June 14 panel at the convention. Read More
Mammoth Biosciences looks to build next-generation CRISPR toolbox
June 7, 2022 -- This month marks the 10th anniversary of the development of CRISPR as a genome-editing tool. While the technology is fairly new, it has made major strides over the past decade, said Mammoth Biosciences co-founder and CEO Trevor Martin in an interview with ScienceBoard.net. Read More
Taking cell therapy to the next level with 3D bioprinting of human tissues
June 6, 2022 -- Aspect Biosystems is working to create breakthrough tissue therapeutics that have the potential to profoundly impact patients with 3D bioprinting of human tissues, contends Eric Roos, chief business development officer. Roos spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Overcoming the blood-brain barrier for gene therapy delivery with AAV capsids
June 2, 2022 -- Current gene delivery to the central nervous system continues to be a challenge, according to Amy Pooler, PhD, vice president of neuroscience at Sangamo Therapeutics. Pooler spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about how Sangamo’s adeno-associated virus (AAV) capsids are designed to overcome the blood-brain barrier. Read More
Decibel Therapeutics develops treatments to restore and improve hearing, balance
May 31, 2022 -- Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD. Reid spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
May 27, 2022 -- Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Dr. Bruce Dezube, senior vice president at Mustang Bio, spoke to ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about the targeting of the CD20 antigen. Read More
Graphite Bio sees its gene editing tech as step above CRISPR
May 26, 2022 -- While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct the underlying genetic defect. CRISPR is the “cut” function and Graphite Bio’s technology is the “cut and paste” capability, Lehrer told ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy
May 26, 2022 -- Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously deliver a functional frataxin gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy. At the American Society of Gene & Cell Therapy 2022 annual meeting, Lexeo presented new preclinical data supporting its FA cardiomyopathy program. Read More
COVID-19 mRNA-based vaccines benefit from decades of research
May 25, 2022 -- 25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in what would become a critical technology used in some of today’s COVID-19 mRNA-based vaccines. Weissman spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC about their research journey. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter